keep me logged in scientists around the world are scrambling to find a vaccine the ultimate covid 19 panacea there are now 70 candidate vaccines in development up from to 44 on march 20 according to a document from who published saturday experts expect it to take between 12 and 18 months to get a vaccine approved for mass use of the 70 covid 19 vaccines in development only three are currently in clinical trials meaning they are being tested on humans clinical trials are designed to assess the safety and efficacy of a new drug and consist of several phases each involving more patients china s cansino biological in partnership with the beijing institute of biotechnology is in the lead with the only candidate vaccine currently in phase two trials u s players moderna and inovio pharmaceuticals are the other two developers testing vaccines on humans and both are currently in phase one the remaining 67 potential vaccines are still only in the pre clinical trial stage to bridge the gap between now and then when a vaccine is approved scientists continue to search for effective treatments with efforts focused on several existing drugs british health care giant astrazeneca has joined this effort announcing today that it would start a clinical trial to assess the potential of calquence a drug already approved for the treatment of leukaemia in the treatment of the immune response associated with covid 19 the trial is expected to open for enrolment in the coming days in the u s and several countries in europe separately there has been some encouraging news on gilead s remdesivir a drug originally developed to treat ebola new data published april 10 in the new england journal of medicine revealed that 68 of 53 hospitalized patients showed improvement after taking the drug however this was not a controlled study rather the data came from a compassionate use program which is where experimental drugs are offered to patients who have a disease with no authorized therapies so experts urge caution when interpreting these findings meanwhile concerns are mounting around the safety of anti malaria drugs chloroquine and hydroxychloroquine touted by u s president donald trump as promising treatments news emerged over the weekend that a chloroquine trial in brazil was cut short after researchers found a high dose was associated with an irregular heartbeat speaking at a coronavirus briefing in geneva monday who executive director of the health emergencies programme dr michael ryan commented the medical and research community are really taking the potential of hydroxychloroquine seriously and chloroquine seriously and it s currently involved in a number of different trials however he added there is no empirical evidence there is no evidence from randomized control trials that it works and clinicians have also been cautioned to look out for side effects of the drug got a confidential news tip we want to hear from you sign up for free newsletters and get more cnbc delivered to your inbox get this delivered to your inbox and more info about our products and services 2020 cnbc llc all rights reserved a division of nbcuniversal data is a real time snapshot data is delayed at least 15 minutes global business and financial news stock quotes and market data and analysis data also provided by 